# NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN

> **NCT05802290** · PHASE3 · COMPLETED · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 124 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Nivolumab 240 MG in 24 ML Injection

## Key facts

- **NCT ID:** NCT05802290
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2020-03-26
- **Final completion:** 2020-03-26
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05802290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05802290, "NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05802290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*